10 Takeover Targets to Watch in 2019
0 Takeover Targets to Watch in 2019
The 2019 pipeline report: Changing the treatment paradigm
The 2019 pipeline report: Changing the treatment paradigm
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
FDA Approves Record-Breaking 59 Novel Drugs in 2018
FDA Approves Record-Breaking 59 Novel Drugs in 2018
5 Biopharma Trends to Watch in 2019
5 Biopharma Trends to Watch in 2019
Seven Trends That Shaped 2018
Seven Trends That Shaped 2018
RNAi: A Coming of Age Story
RNAi: A Coming of Age Story
Record-Setting Pace for New Drug Approvals in 2018
Record-Setting Pace for New Drug Approvals in 2018
Is the Biotech Bull Market Over?
Is the Biotech Bull Market Over?
Akcea Therapeutics and Ionis Pharmaceuticals Snag FDA Approval for Tegsedi
Akcea Therapeutics and Ionis Pharmaceuticals Snag FDA Approval for Tegsedi
With Hemlibra, Roche seeks to break into tight hemophilia circle
With Hemlibra, Roche seeks to break into tight hemophilia circle
10 biotechs set to shake up the industry’s top ranks
10 biotechs set to shake up the industry’s top ranks
Alnylam Indicates Phase III Trial Is Successful Thus Far
Alnylam Indicates Phase III Trial Is Successful Thus Far
FDA Approves Eight Novel Drugs in August
FDA Approves Eight Novel Drugs in August
RNAi: The Monoclonal Antibody of the 2020s?
There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals‘ Onpattro, got approved on August 10. That makes 2018 a landmark year. But another … Continue Reading RNAi: The Monoclonal Antibody of the 2020s?
After Alnylam’s solo maiden launch, here comes the tricky bit
14 years after floating on Nasdaq, and with a strategic rebranding as well as $2.4bn of accumulated losses under its belt, Alnylam on Friday achieved its proudest milestone yet: its … Continue Reading After Alnylam’s solo maiden launch, here comes the tricky bit
